Idorsia Ltd. (IDRSF)
5.38
0.00 (0.00%)
USD |
OTCM |
Oct 09, 16:00
Idorsia Cash from Operations (Quarterly) : -43.01M for June 30, 2026
Cash from Operations (Quarterly) Chart
Historical Cash from Operations (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -43.01M |
| March 31, 2026 | -33.98M |
| December 31, 2025 | -54.43M |
| September 30, 2025 | -30.12M |
| June 30, 2025 | -52.47M |
| March 31, 2025 | -74.25M |
| December 31, 2024 | -7.366M |
| September 30, 2024 | -116.19M |
| June 30, 2024 | -107.48M |
| March 31, 2024 | -135.30M |
| December 31, 2023 | -125.10M |
| September 30, 2023 | -86.27M |
| June 30, 2023 | -213.64M |
| March 31, 2023 | -270.25M |
| December 31, 2022 | -229.22M |
| September 30, 2022 | -202.54M |
| June 30, 2022 | -211.75M |
| March 31, 2022 | -257.54M |
| December 31, 2021 | -214.58M |
| Date | Value |
|---|---|
| September 30, 2021 | -126.65M |
| June 30, 2021 | -137.99M |
| March 31, 2021 | -165.72M |
| December 31, 2020 | -136.51M |
| September 30, 2020 | -99.57M |
| June 30, 2020 | -45.39M |
| March 31, 2020 | -109.42M |
| December 31, 2019 | -127.46M |
| September 30, 2019 | -126.21M |
| June 30, 2019 | -101.94M |
| March 31, 2019 | -109.54M |
| December 31, 2018 | -125.19M |
| September 30, 2018 | -94.92M |
| June 30, 2018 | -64.92M |
| March 31, 2018 | -74.62M |
| December 31, 2017 | 147.65M |
| September 30, 2017 | -56.76M |
| June 30, 2017 | 102.79M |
| March 31, 2017 | -96.42M |
Cash From Operations Definition
Represents the net cash flow from the company's business operations.
Cash from Operations (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Operations (Quarterly) Benchmarks
| Basilea Pharmaceutica AG | -- |
| Santhera Pharmaceuticals Holding AG | -- |
| BeOne Medicines Ltd. | 463.60M |
| AC Immune SA | -- |
| CRISPR Therapeutics AG | -83.50M |
Cash from Operations (Quarterly) Related Metrics
| Cash from Investing (Quarterly) | -3.521M |
| Cash from Financing (Quarterly) | 38.69M |
| Free Cash Flow | -172.44M |
| Free Cash Flow Per Share (Quarterly) | -0.1818 |
| Free Cash Flow to Equity (Quarterly) | -41.35M |
| Free Cash Flow to Firm (Quarterly) | -18.59M |
| Free Cash Flow Yield | -13.20% |